Matthew J. Frigault

Broad Institute — United States

Medicine · Health Sciences

45h-index12.0kcitations302works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(232), Lymphoma Diagnosis and Treatment(32), Virus-based gene therapy research(26), Immune Cell Function and Interaction(26), Integrated Circuits and Semiconductor Failure Analysis(26)

Publications300 total

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Leukemia·2025Open Access
Tumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy
Neuro-Oncology·2025
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Blood·2025Open Access
Absolute lymphocyte count is predictive of response to salvage therapies for post-CAR T failure
Blood·2025Open Access
Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry
Blood·2025Open Access
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Blood·2025
A phase 1b/2a study of CTO1681 for the prevention of cytokine release syndrome in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy
Blood·2025Open Access
Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Blood·2025Open Access
Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.
Blood·2025
Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials
Blood·2025
The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes
Blood·2025
Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma
Blood·2025Open Access
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
RADT-42. NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
Neuro-Oncology·2025Open Access
NCMP-17. Clinical Presentation, Management and Outcome of Tumor inflammation-associated neurotoxicity (TIAN) in CNS lymphoma treated with CD19-CAR T-cell therapy
Neuro-Oncology·2025Open Access
EXTH-47. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology·2025Open Access
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
Transplantation and Cellular Therapy·2025· 1 cited
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
Transplantation and Cellular Therapy·2025· 1 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Marcela V. Maus(29), Mark B. Leick(12), Bryan D. Choi(9), Kathleen Gallagher(9), Sarah Nikiforow(8), Philippe Armand(8), Amanda A. Bouffard(8), Rebecca C. Larson(8), Irene Scarfò(8), Yi‐Bin Chen(8), Andrea Schmidts(7), Jeremy S. Abramson(7), Tomas G. Neilan(6), Ana P. Castaño(6), Miguel‐Angel Perales(6), Charlotte Graham(6), Caron A. Jacobson(6), Jörg Dietrich(6), Stefanie R. Bailey(5), Noopur Raje(5)